Applications of functionalized fullerenes in tumor theranostics

Theranostics

Volumn 2, Issue 3, 2012, Pages 238-250

  Chen, Zhiyun ^a   Ma, Lijing ^a   Liu, Ying ^a   Chen, Chunying ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer diagnosis; Cancer therapy; Functionalized fullerenes; Nanoparticles; Theranostics

Indexed keywords

CARBOXYL GROUP; CONTRAST MEDIUM; FULLERENE DERIVATIVE; GADODIAMIDE; GADOLINIUM CHELATE; GADOTERIDOL; MACROGOL; NANOPARTICLE; PORPHYRIN; PULLULAN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOSTIMULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PHOTOACOUSTIC SPECTROSCOPY; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ULTRASOUND;

EID: 84864546864     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3509     Document Type: Review

References (85)

1. Kroto HW, Heath JR, O'Brien SC, et al. C60: Buckminsterfullerene. Nature. 1985; 318: 162-3.
2. Bosi S, Da Ros T, Spalluto G, et al. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 2003; 38: 913-23.
3. Kato H, Kanazawa Y, Okumura M, et al. Lanthanoid endohedral metallofullerenols for MRI contrast agents. J Am Chem Soc. 2003; 125: 4391-7.
4. Arbogast JW, Darmanyan AP, Foote CS, et al. Photophysical properties of C60. J Phys Chem. 1991; 95: 11-2.
5. Liu Z, Kiessling F, Gatjens J. Advanced nanomaterials in multimodal imaging: design, functionalization, and biomedical applications. J Nanomater. 2010.
6. Na HB, Hyeon T. Nanostructured T1 MRI contrast agents. J Mater Chem. 2009; 19: 6267-73.
7. Mody VV, Nounou MI, Bikram M. Novel nanomedicine-based MRI contrast agents for gynecological malignancies. Adv Drug Del Rev. 2009; 61: 795-807.
8. Sitharaman B, Bolskar RD, Rusakova I, et al. Gd@C60[C(COOH)2]10 and Gd@C60(OH)x: Nanoscale aggregation studies of two metallofullerene MRI contrast agents in aqueous solution. Nano Lett. 2004; 4: 2373-8.
9. Liu Y, Jiao F, Qiu Y, et al. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity. Biomaterials. 2009; 30: 3934-45.
10. Mikawa M, Kato H, Okumura M, et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem. 2001; 12: 510-4.
11. Shu CY, Wang CR, Zhang JF, et al. Organophosphonate functionalized Gd@C82 as a magnetic resonance imaging contrast agent. Chem Mater. 2008; 20: 2106-9.
12. Grushko YS, Kozlov VS, Sedov VP, et al. MRI-contrasting system based on water-soluble fullerene/Gd-metallofullerene mixture. Fuller Nanotub Car N. 2010; 18: 417-21.
13. Bolskar RD, Benedetto AF, Husebo LO, et al. First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent. J Am Chem Soc. 2003; 125: 5471-8.
14. Sitharaman B, Tran LA, Pham QP, et al. Gadofullerenes as nanoscale magnetic labels for cellular MRI. Contrast Media Mol Imaging. 2007; 2: 139-46.
15. Fatouros PP, Corwin FD, Chen ZJ, et al. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology. 2006; 240: 756-64.
16. Zhang JF, Fatouros PP, Shu CY, et al. High relaxivity trimetallic nitride (Gd3N) metallofullerene MRI contrast agents with optimized functionality. Bioconjug Chem. 2010; 21: 610-5.
17. Shu CY, Corwin FD, Zhang JF, et al. Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high (1)H relaxivity. Bioconjug Chem. 2009; 20: 1186-93.
18. Shu CY, Ma XY, Zhang JF, et al. Conjugation of a water-soluble gadolinium endohedral fulleride with an antibody as a magnetic resonance imaging contrast agent. Bioconjug Chem. 2008; 19: 651-5.
19. Fillmore HL, Shultz MD, Henderson SC, et al. Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors. Nanomedicine. 2011; 6: 449-58.
20. Krishna V, Singh A, Sharma P, et al. Polyhydroxy fullerenes for non-invasive cancer imaging and therapy. Small. 2010; 6: 2236-41.
21. Krishna V, Stevens N, Koopman B, et al. Optical heating and rapid transformation of functionalized fullerenes. Nat Nanotechnol. 2010; 5: 330-4.
22. Satoh M, Takayanag I. Pharmacological studies on Fullerene(C60), a novel carbon allotrope, and its derivatives. J Pharmacol Sci. 2006; 100: 513-8.
23. Tabata Y, Ikada Y. Biological functions of fullerene. Pure Appl Chem. 1999; 71: 2047-53.
24. Tokuyama H, Yamago S, Nakamura E, et al. Photoinduced biochemical-activity of fullerene carboxylic-acid. J Am Chem Soc. 1993; 115: 7918-9.
25. Nakajima N, Nishi C, Li FM, et al. Photo-induced cytotoxicity of water-soluble fullerene. Fullerene Sci Technol. 1996; 4: 1-19.
26. Liu J, Tabata Y. Photodynamic therapy of fullerene modified with pullulan on hepatoma cells. J Drug Target. 2010; 18: 602-10.
27. Liu J, Tabata Y. Photodynamic antitumor activity of fullerene modified with poly(ethylene glycol) with different molecular weights and terminal structures. J Biomater Sci Polym Ed. 2011; 22: 297-312.
28. Ji ZQ, Sun HF, Wang HF, et al. Biodistribution and tumor uptake of C60(OH)x in mice. J Nanopart Res. 2006; 8: 53-63.
29. Liu J, Ohta S, Sonoda A, et al. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J Control Release. 2007; 117: 104-10.
30. Yamakoshi Y, Umezawa N, Ryu A, et al. Active Oxygen Species Generated from Photoexcited Fullerene (C60) as Potential Medicines: O2-• versus 1O2. J Am Chem Soc. 2003; 125: 12803-9.
31. Zhao B, He YY, Bilski PJ, et al. Pristine (C60) and Hydroxylated [C60(OH)24] Fullerene Phototoxicity towards HaCaT Keratinocytes: Type I vs Type II Mechanisms. Chem Res Toxicol. 2008; 21: 1056-63.
32. Zhao B, Bilski PJ, He YY, et al. Photo-induced Reactive Oxygen Species Generation by Different Water-soluble Fullerenes (C60) and Their Cytotoxicity in Human Keratinocytes. Photochem Photobiol. 2008; 84: 1215-23.
33. Alvarez MG, Prucca C, Milanesio ME, et al. Photodynamic activity of a new sensitizer derived from porphyrin-C60 dyad and its biological consequences in a human carcinoma cell line. Int J Biochem Cell Biol. 2006; 38: 2092-101.
34. Mroz P, Pawlak A, Satti M, et al. Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free Radical Biol Med. 2007; 43: 711-9.
35. Mroz P, Xia Y, Asanuma D, et al. Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma. Nanomedicine. 2011; Doi:10.1016/j.nano.2011.04.007.
36. Diener MD, Alford JM, Kennel SJ, et al. Pb-212@C60 and its water-soluble derivatives: Synthesis, stability, and suitability for radioimmunotherapy. J Am Chem Soc. 2007; 129: 5131-8.
37. Shultz MD, Duchamp JC, Wilson JD, et al. Encapsulation of a radiolabeled cluster inside a fullerene cage, 177LuxLu(3-x)N@C80: an interleukin-13-conjugated radio-labeled metallofullerene platform. J Am Chem Soc. 2010; 132: 4980-1.
38. Liu Y, Jiao F, Qiu Y, et al. Immunostimulatory properties and enhanced TNF-α mediated cellular immunity for tumor therapy by C60(OH)20 nanoparticles. Nanotechnology. 2009; 20: 415102-11.
39. Li W, Zhao L, Wei T, et al. The inhibition of death receptor mediated apoptosis through lysosome stabilization following internalization of carboxyfullerene nanoparticles. Biomaterials. 2011; 32: 4030-41.
40. Chen C, Xing G, Wang J, et al. Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett. 2005; 5: 2050-7.
41. Zhu JD, Ji ZQ, Wang J, et al. Tumor-inhibitory effect and immunomodulatory activity of fullerol C60(OH)x. Small. 2008; 4: 1168-75.
42. Jiao F, Liu Y, Qu Y, et al. Studies on anti-tumor and antimetastatic activities of fullerenol in a mouse breast cancer model. Carbon. 2010; 48: 2231-43.
43. Liang XJ, Meng H, Wang YZ, et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A. 2010; 107: 7449-54.
44. Zhang Q, Yang WJ, Man N, et al. Autophagymediated chemosensitization in cancer cells by fullerene C60 nanocrystal. Autophagy. 2009; 5: 1107-17.
45. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-6.
46. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010; 468: 829-33.
47. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010; 468: 824-8.
48. Kou B, Li Y, Zhang L, et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp Mol Pathol. 2004; 76: 129-37.
49. Meng H, Xing G, Sun B, et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano. 2010; 4: 2773-83.
50. Yin JJ, Lao F, Fu PP, et al. The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials. Biomaterials. 2009; 30: 611-21.
51. Yin JJ, Lao F, Meng J, et al. Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger. Mol Pharmacol. 2008; 74: 1132-40.
52. Injac R, Perse M, Obermajer N, et al. Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. Biomaterials. 2008; 29: 3451-60.
53. Injac R, Perse M, Cerne M, et al. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials. 2009; 30: 1184-96.
54. Injac R, Boskovic M, Perse M, et al. Acute doxorubicin ne-phrotoxicity in rats with malignant neoplasm can be successfully treated with fullerenol C60(OH)24 via suppression of oxidative stress. Pharmacol Rep. 2008; 60: 742-9.
55. Injac R, Radic N, Govedarica B, et al. Acute doxorubicin pulmotoxicity in rats with malignant neoplasm is effectively treated with fullerenol C60(OH)24 through inhibition of oxidative stress. Pharmacol Rep. 2009; 61: 335-42.
56. Yang D, Zhao Y, Guo H, et al. [Gd@C82(OH)22]n nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano. 2010; 4: 1178-86.
57. Wang BB, Yang D, Sun BY, et al. An anti-tumor nanoparticle, [Gd@C82(OH)22]n, induces macrophage activation. J Nanosci Nanotechnol. 2011; 11: 2321-9.
58. Chen BX, Wilson SR, Das M, et al. Antigenicity of fullerenes: Antibodies specific for fullerenes and their characteristics. Proc Natl Acad Sci U S A. 1998; 95: 10809-13.
59. Erlanger BF, Chen BX, Zhu M, et al. Binding of an Anti-Fullerene IgG Monoclonal Antibody to Single Wall Carbon Nanotubes. Nano Lett. 2001; 1: 465-7.
60. Braden BC, Goldbaum FA, Chen BX, et al. X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: Biomolecular recognition of C60. Proc Natl Acad Sci U S A. 2000; 97: 12193-7.
61. Shintani T, Klionsky DJ. Autophagy in Health and Disease: A Double-Edged Sword. Science. 2004; 306: 990-5.
62. Wei PF, Zhang L, Lu Y, et al. C60(Nd) nanoparticles enhance chemotherapeutic susceptibility of cancer cells by modulation of autophagy. Nanotechnology. 2010; 21: 495101.
63. Li YF, Chen C. Fate and Toxicity of metallic and metal-containing nanoparticles for biomedical applications. Small. 2011; 7: 2965-80.
64. Johnston HJ, Hutchison GR, Christensen FM, et al. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci. 2010; 114: 162-82
65. Yamago S, Tokuyama H, Nakamura E, et al. Invivo biological behavior of a water-miscible fullerene: C-14 labeling, absorption, distribution, excretion and acute toxicity. Chem Biol. 1995; 2: 385-9.
66. BullardDillard R, Creek KE, Scrivens WA, et al. Tissue sites of uptake of C-14-labeled C60. Bioorg Chem. 1996; 24: 376-85.
67. Gharbi N, Pressac M, Hadchouel M, et al. [60]Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005; 5: 2578-85.
68. Li QN, Xiu Y, Zhang XD, et al. Preparation of Tc-99m-C60(OH)x and its biodistribution studies. Nucl Med Biol. 2002; 29: 707-10.
69. Cagle DW, Kennel SJ, Mirzadeh S, et al. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci U S A. 1999; 96: 5182-7.
70. Wang J, Chen C, Li B, et al. Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice. Biochem Pharmacol. 2006; 71: 872-81.
71. Baker GL, Gupta A, Clark ML, et al. Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and micro-particles. Toxicol Sci. 2008; 101: 122-31.
72. Fujita K, Morimoto Y, Ogami A, et al. Gene expression profiles in rat lung after inhalation exposure to C60 fullerene particles. Toxicology. 2009; 258: 47-55.
73. Chen HHC, Yu C, Ueng TH, et al. Acute and subacute toxicity study of water-soluble polyalkylsulfonated C60 in rats. Toxicol Pathol. 1998; 26: 143-51.
74. Mori T, Takada H, Ito S, et al. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology. 2006; 225: 48-54.
75. Zhao F, Zhao Y, Liu Y, et al. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small. 2011; 7: 1322-37.
76. Yamawaki H, Iwai N. Cytotoxicity of water-soluble fullerene in vascular endothelial cells. Am J Physiol Cell Physiol. 2006; 290: C1495-C1502.
77. Marchesan S, Da Ros T, Spalluto G, et al. Anti-HIV properties of cationic fullerene derivatives. Bioorg Med Chem Lett. 2005; 15: 3615-8.
78. Mashino T, Shimotohno K, Ikegami N, et al. Human immuno-deficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg Med Chem Lett. 2005; 15: 1107-9.
79. Tegos GP, Demidova TN, Arcila-Lopez D, et al. Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol. 2005; 12: 1127-35.
80. Lu ZS, Dai TH, Huang LY, et al. Photodynamic therapy with a cationic functionalized fullerene rescues mice from fatal wound infections. Nanomedicine. 2010; 5: 1525-33.
81. Srdjenovic B, Milic-Torres V, Grujic N, et al. Antioxidant properties of fullerenol C60(OH)24 in rat kidneys, testes, and lungs treated with doxorubicin. Toxicol Mech Methods. 2010; 20: 298-305.
82. Dugan LL, Lovett EG, Quick KL, et al. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord. 2001; 7: 243-6.
83. Isobe H, Nakanishi W, Tomita N, et al. Nonviral gene delivery by tetraamino fullerene. Mol Pharm. 2006; 3: 124-34.
84. Klumpp C, Lacerda L, Chaloin O, et al. Multifunctionalised cationic fullerene adducts for gene transfer: design, synthesis and DNA complexation. Chem Commun (Camb). 2007;: 3762-4.
85. Sitharaman B, Zakharian TY, Saraf A, et al. Water-soluble fullerene (C60) derivatives as nonviral gene-delivery vectors. Mol Pharm. 2008; 5: 567-78.